Concarlo Holdings is an exciting new biotech startup developing novel therapeutics to target ER/PR+ Her2- breast cancer.
Based on the work of Dr. Stacy W. Blain at SUNY Downstate Medical Center, Concarlo addresses unmet needs in oncology. Concarlo is the exclusive licensee of patent application(s) based from Dr. Blain's SUNY DMC lab.
Innovation for combating drug resistance and diagnosing the right drugs is a hallmark of Concarlo’s R&D mission and technologies. We believe in groundbreaking 21st century focus on targeted therapies and diagnostics in cancer care